A phase 1 B, open-label, dose-escalation study of bortezomib (Btz) in combination with gemcitabine (G) and cisplatin (C) in the first-line treatment of patients with advanced solid tumors: preliminary results

J. Voortman, E. F. Smit, B. C. Kuenen, H. van de Velde, G. Giaccone

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)425-425
JournalEuropean Journal of Cancer. Supplement
Issue number2
Publication statusPublished - Oct 2005

Cite this